An investigation on behalf of investors in Vaccinex, Inc. (NASDAQ: VCNX) shares over potential wrongdoing at Vaccinex, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 10/30/2019 -- An investigation was announced for investors in shares of Vaccinex, Inc. (NASDAQ: VCNX) over potential breaches of fiduciary duties by certain directors at Vaccinex, Inc..
Investors who purchased shares of Vaccinex, Inc. (NASDAQ: VCNX) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vaccinex, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Rochester, NY based Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. On August 9, 2018, Vaccinex, Inc. announced the pricing for its initial public offering. Vaccinex, Inc sold 3.33 million shares at $12.00 per share. Since then shares of Vaccinex, Inc. (NASDAQ: VCNX) declined to as low as $3.94 per share on July 26, 2019.
Those who purchased shares of Vaccinex, Inc. (NASDAQ: VCNX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in conftact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels